INTEGRATED BIOPHARMA INC (INBP) Financial Statements (2024 and earlier)

Company Profile

Business Address 225 LONG AVENUE
HILLSIDE, NJ 07205
State of Incorp. DE
Fiscal Year End June 30
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

3/31/2024
MRQ
12/31/2023
MRQ
6/30/2023
6/30/2022
6/30/2021
6/30/2020
6/30/2019
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments7321,316331210402475
Cash and cash equivalents7321,316331210402475
Receivables3,7334,5114,8885,7765,5074,439
Inventory, net of allowances, customer advances and progress billings12,14910,26111,05511,69510,1018,819
Inventory12,14910,26111,05511,69510,1018,819
Other current assets451284352317451346
Total current assets:17,06516,37216,62617,99816,46114,079
Noncurrent Assets
Operating lease, right-of-use asset2,2472,6231,8672,3652,824
Property, plant and equipment1,5581,6531,9101,7421,6961,778
Deposits noncurrent assets5757496780115
Deferred income tax assets4,7944,7264,7983,2681,883
Deferred tax assets, net534
Other undisclosed noncurrent assets      3,284
Total noncurrent assets:8,6569,0598,6247,4426,4835,711
TOTAL ASSETS:25,72125,43125,25025,44022,94419,790
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities3,3052,2663,2093,4964,3583,855
Accounts payable3,3052,2663,2093,4964,3583,855
Debt2842321,4572,8231,047
Due to related parties    67
Other undisclosed current liabilities2,5002,5202,0224,2835,9187,384
Total current liabilities:5,8334,8285,2639,23613,09912,353
Noncurrent Liabilities
Long-term debt and lease obligation  71,4121,8703,7782,722
Long-term debt, excluding current maturities  753 1,4362,722
Liabilities, other than long-term debt1,3221,735    
Operating lease, liability1,3221,7351,3591,8702,342
Other undisclosed noncurrent liabilities   (1,359)(1,870)(2,342)2,822
Total noncurrent liabilities:1,3221,7421,4121,8703,7785,544
Total liabilities:7,1556,5706,67511,10616,87717,897
Equity
Equity, attributable to parent18,56618,86118,57514,3346,0671,893
Common stock606060605959
Treasury stock, value(99)(99)(99)(99)(99)(99)
Additional paid in capital51,38551,23950,91950,51650,26350,197
Accumulated deficit(32,780)(32,339)(32,305)(36,143)(44,156)(48,264)
Total equity:18,56618,86118,57514,3346,0671,893
TOTAL LIABILITIES AND EQUITY:25,72125,43125,25025,44022,94419,790

Income Statement (P&L) ($ in thousands)

3/31/2024
TTM
12/31/2023
TTM
6/30/2023
6/30/2022
6/30/2021
6/30/2020
6/30/2019
Revenues50,51650,67256,24663,55952,76949,977
Cost of revenue
(Cost of Goods and Services Sold)
(47,170)(46,611)(49,694)(54,079)(46,042)(43,755)
Gross profit:3,3464,0616,5529,4806,7276,222
Operating expenses(3,729)(3,941)(3,807)(3,696)(3,468)(3,518)
Operating income (loss):(383)1202,7455,7843,2592,704
Nonoperating income (expense)12(20)(148)1,463(171)(662)
Other nonoperating income (expense)3140355751(18)
Interest and debt expense(17)(52)(128)1,639(397)(630)
Other undisclosed income (loss) from continuing operations before equity method investments, income taxes    (1,639)397630
Income (loss) from continuing operations before equity method investments, income taxes:(388)482,4697,2473,0882,042
Other undisclosed income from continuing operations before income taxes1952128   
Income (loss) from continuing operations before income taxes:(369)1002,5977,2473,0882,042
Income tax expense (benefit)(16)(134)1,2417661,020(354)
Income (loss) from continuing operations:(385)(34)3,8388,0134,1081,688
Income before gain (loss) on sale of properties:3,8388,0134,1081,688
Net income (loss) available to common stockholders, diluted:(385)(34)3,8388,0134,1081,688

Comprehensive Income ($ in thousands)

3/31/2024
TTM
12/31/2023
TTM
6/30/2023
6/30/2022
6/30/2021
6/30/2020
6/30/2019
Net income (loss):(385)(34)3,8388,0134,1081,688
Comprehensive income (loss), net of tax, attributable to parent:(385)(34)3,8388,0134,1081,688

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: